Emerging Imaging and Laboratory Biomarkers for MS Progression

In this episode, the panel examines promising new tools for detecting and predicting disease progression in multiple sclerosis. They discuss the growing role of imaging biomarkers, with special focus on paramagnetic rim lesions, which mark areas of chronic inflammation and may help identify patients at greater risk of worsening disability. Laboratory biomarkers, such as neurofilament light chain and GFAP, are explored for their ability to signal underlying nerve cell damage, but panelists highlight that these tests are not yet widely available and face practical hurdles like insurance coverage and uncertain interpretation in routine clinical care. The group notes that these emerging tools can offer critical information on disease activity not revealed by standard MRI, but they also stress the need for more research to determine how best to use them for guiding treatment decisions. The conversation concludes with cautious optimism about how these advancements may soon enhance MS monitoring.